2365 related articles for article (PubMed ID: 15521969)
1. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
3. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
[TBL] [Abstract][Full Text] [Related]
6. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease.
Martin NM; Patel M; Nijher GM; Misra S; Murphy E; Meeran K
Clin Endocrinol (Oxf); 2012 Oct; 77(4):621-7. PubMed ID: 22443227
[TBL] [Abstract][Full Text] [Related]
8. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.
Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK
J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128
[TBL] [Abstract][Full Text] [Related]
9. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism?
Vijayakumar V; Ali S; Nishino T; Nusynowitz M
Clin Nucl Med; 2006 Nov; 31(11):688-9. PubMed ID: 17053385
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine treatment of hyperthyroidism. Success rate and influence of thyrostatic medication.
Ghadban WK; Zirie MA; Al-Khateeb DA; Jayyousi AA; Mobayedh HM; El-Aloosy AS
Saudi Med J; 2003 Apr; 24(4):347-51. PubMed ID: 12754531
[TBL] [Abstract][Full Text] [Related]
11. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children.
Nebesio TD; Siddiqui AR; Pescovitz OH; Eugster EA
J Pediatr; 2002 Jul; 141(1):99-103. PubMed ID: 12091858
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy.
Khanna CM; Magdam M; Ravishankar L; Dham DN; Chugh P
J Assoc Physicians India; 1995 Oct; 43(10):685-8. PubMed ID: 8773004
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine in the treatment of Graves' disease.
Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H
Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves' hyperthyroidism.
Leslie WD; Peterdy AE; Dupont JO
J Nucl Med; 1998 Apr; 39(4):712-6. PubMed ID: 9544686
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
18. Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay.
Hovens GC; Heemstra KA; Buiting AM; Stokkel MP; Karperien M; Ballieux BE; Pereira AM; Romijn JA; Smit JW
Nucl Med Commun; 2007 Feb; 28(2):123-7. PubMed ID: 17198353
[TBL] [Abstract][Full Text] [Related]
19. Relevance of cause of hyperthyroidism in determining its management.
Veneman TF; Weymer M; Tjabbes T; van Haeften TW
Neth J Med; 1989 Dec; 35(5-6):303-8. PubMed ID: 2635287
[TBL] [Abstract][Full Text] [Related]
20. Increased cancer incidence after radioiodine treatment for hyperthyroidism.
Metso S; Auvinen A; Huhtala H; Salmi J; Oksala H; Jaatinen P
Cancer; 2007 May; 109(10):1972-9. PubMed ID: 17393376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
